- Conditions
- HIV Infections
- Interventions
- p24CE1/2 pDNA Vaccine, p55^gag pDNA Vaccine, IL-12 pDNA Adjuvant, Placebo, Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device
- Biological · Device
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 3
- States / cities
- San Francisco, California • Decatur, Georgia • Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 97
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy
- Interventions
- VGX-3400X
- Biological
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Overland Park, Kansas • Rockville, Maryland
- Conditions
- Prostate Cancer, Breast Cancer Female
- Interventions
- Exercise
- Behavioral
- Lead sponsor
- Celina Shirazipour
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Healthy Volunteers
- Interventions
- dMAb AZD5396, dMAb AZD8076, CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device, Hylenex, CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device
- Combination Product · Drug
- Lead sponsor
- Pablo Tebas
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Bipolar Depression
- Interventions
- PF-04455242, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Prostate Cancer
- Interventions
- Docetaxel, Carboplatin, Etoposide, Cisplatin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 2
- States / cities
- San Francisco, California • Houston, Texas
- Conditions
- Data Collection
- Interventions
- Atrial Flutter Ablation
- Device
- Lead sponsor
- EPD Solutions, A Philips Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 566 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Florida City, Florida
- Conditions
- Respiratory Papillomatosis
- Interventions
- INO-3107, CELLECTRA® 2000
- Drug · Device
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Sacramento, California • Atlanta, Georgia + 7 more
- Conditions
- Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation
- Interventions
- Hybrid: AtriCure Bipolar System & EP ablation procedure
- Device
- Lead sponsor
- AtriCure, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 5
- States / cities
- Stanford, California • Nashville, Tennessee • Plano, Texas + 2 more
- Conditions
- Ventricular Tachycardia, Cardiomyopathy, Premature Ventricular Contractions
- Interventions
- stereotactic body radiotherapy (SBRT)
- Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Recurrent Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer, Small Cell Lung Cancer, Small Cell Lung Carcinoma, Refractory Small Cell Lung Cancer, Extrapulmonary Small Cell Carcinoma, Neuroendocrine Carcinoma, Poorly Differentiated Neuroendocrine Carcinoma, High-Grade Neuroendocrine Carcinoma
- Interventions
- Autologous B7-H3 CAR T, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Atrial Fibrillation, Hypertension
- Interventions
- catheter ablation, renal sympathetic denervation
- Procedure
- Lead sponsor
- Meshalkin Research Institute of Pathology of Circulation
- Network
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Short Hills, New Jersey
- Conditions
- HIV-1-infection
- Interventions
- Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 689 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 40
- States / cities
- Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more
- Conditions
- Cancer
- Interventions
- MedPulser Electroporation with bleomycin
- Combination Product
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Psychosis, Substance Use, Substance Use Disorders, Family, Cannabis, Marijuana, Alcohol, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Mental Disorder
- Interventions
- CRAFT-EP, TAU
- Behavioral
- Lead sponsor
- Mclean Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Belmont, Massachusetts
- Conditions
- Head and Neck Squamous Cell Cancer
- Interventions
- INO-3112, CELLECTRA™-5P
- Biological · Device
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Ventricular Tachycardia
- Interventions
- Market Approved RF Ablation System, FlexAbility SE Ablation Catheter
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 592 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma, Iris Melanoma, Metastatic Intraocular Melanoma, Mucosal Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IIC Melanoma, Stage IIIA Intraocular Melanoma, Stage IIIA Melanoma, Stage IIIB Intraocular Melanoma, Stage IIIB Melanoma, Stage IIIC Intraocular Melanoma, Stage IIIC Melanoma, Stage IV Intraocular Melanoma, Stage IV Melanoma
- Interventions
- gp100 antigen, tyrosinase peptide, recombinant MAGE-3.1 antigen, multi-epitope melanoma peptide vaccine, incomplete Freund's adjuvant, Montanide ISA 51 VG, agatolimod sodium, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Anemia
- Interventions
- Epoetin alfa, methoxy polyethylene glycol-epoetin beta [Mircera]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Bakersfield, California • Chula Vista, California + 26 more
- Conditions
- HIV, Therapeutic Vaccine
- Interventions
- rVSV, IL-12 pDNA adjuvant, HIV-Mag pDNA, Placebo
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Acute Lung Injury, Acute Respiratory Distress Syndrome
- Interventions
- Placement of an esophageal balloon measurements, Low tidal volume ventilation, Transpulmonary pressure-directed ventilation (EPVent)
- Procedure · Other
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Interstitial Cystitis, Chronic Prostatitis
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 424 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2014
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Los Angeles, California • Stanford, California + 5 more
- Conditions
- Hypercholesterolemia
- Interventions
- Atorvastatin suspension, Lipitor
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- HIV Infections
- Interventions
- sD-NP-GT8 DNA, IL-12 DNA, Trimer 4571, 3M-052-AF, Alum
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • San Francisco, California • Boston, Massachusetts